An analysis of the personal cord stem cell banking market in the Russian Federation showed that by the end of 2024, approximately 86,000 personal cord blood samples had been stored across 12 cord blood banks operating in our country.
Gemabank held the largest share of personal stem cell samples deposited in 2024 among cord blood banks, accounting for 42 %.
In 2024, Gemabank accepted 41 % more samples for banking than in 2023, increasing its total banking capacity for all biomaterials to 43,479 samples.
The demand for samples (number of transplantations) is an important indicator for the personal banking industry. It reflects the healthcare system's readiness to use this biomaterial and motivates prospective parents to preserve cord stem cells.
By the end of 2024, Gemabank had allocated 61 stem cell samples for therapeutic use, representing 1/600 of the total stored pool.
In 2024, the birth rate declined by 3.4 % compared to 2023, while the penetration rate of cord stem cell preservation services reached 0.34 %. Between 2009 and 2016, this figure ranged from 0.29 % to 0.39 %.
Market analysis indicates that the cord blood biobanking sector is relatively stable. The share of companies depends primarily on their strategic approach. While service penetration rates fluctuate in response to the country's birth rate and economic conditions, this sector has demonstrated resilience even during times of crisis.
IMCB (Gemabank), a biotechnology company within Artgen Biotech Group (MOEX: ABIO), focuses on personal stem cell banking and the development of gene therapy drugs targeting blood and immune system disorders.